These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1477452)

  • 1. Current treatment recommendations for leishmaniasis.
    Moss JT; Wilson JP
    Ann Pharmacother; 1992 Nov; 26(11):1452-5. PubMed ID: 1477452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.
    Vakil NH; Fujinami N; Shah PJ
    Pharmacotherapy; 2015 May; 35(5):536-45. PubMed ID: 25940658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmaniasis and poverty.
    Alvar J; Yactayo S; Bern C
    Trends Parasitol; 2006 Dec; 22(12):552-7. PubMed ID: 17023215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmaniasis chemotherapy--challenges and opportunities.
    Croft SL; Olliaro P
    Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
    Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
    Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmaniasis.
    Burza S; Croft SL; Boelaert M
    Lancet; 2018 Sep; 392(10151):951-970. PubMed ID: 30126638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmaniasis.
    Herwaldt BL
    Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
    Ali A
    Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy of leishmaniasis: present challenges.
    Uliana SRB; Trinconi CT; Coelho AC
    Parasitology; 2018 Apr; 145(4):464-480. PubMed ID: 28103966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmaniasis in immunosuppressed individuals.
    van Griensven J; Carrillo E; López-Vélez R; Lynen L; Moreno J
    Clin Microbiol Infect; 2014 Apr; 20(4):286-99. PubMed ID: 24450618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-kala-azar dermal leishmaniasis caused by Leishmania infantum in an immunocompetent patient.
    Sánchez-Albisua B; Polimón I; Pérez-Tato B; Marinero S; Fernández-López P
    Int J Dermatol; 2013 Jul; 52(7):897-9. PubMed ID: 23675968
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
    Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
    J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short report: Treatment failure due to mixed infection by different strains of the parasite Leishmania infantum.
    Antoniou M; Doulgerakis C; Pratlong F; Dedet JP; Tselentis Y
    Am J Trop Med Hyg; 2004 Jul; 71(1):71-2. PubMed ID: 15238692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current scenario of drug development for leishmaniasis.
    Croft SL; Seifert K; Yardley V
    Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management.
    Handler MZ; Patel PA; Kapila R; Al-Qubati Y; Schwartz RA
    J Am Acad Dermatol; 2015 Dec; 73(6):911-26; 927-8. PubMed ID: 26568336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lingual leishmaniasis complicating visceral disease.
    Mazumder SA; Pandey S; Brewer SC; Baselski VS; Weina PJ; Land MA; Fleckenstein JM
    J Travel Med; 2010; 17(3):212-4. PubMed ID: 20536896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmaniasis and its relevance to UK Armed Forces.
    Preedy HC; Bailey MS
    J R Nav Med Serv; 2014; 100(3):238-43. PubMed ID: 25895401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.